Tensys Medical, Inc., a leader in the development and commercialization of continuous, non-invasive hemodynamic patient monitoring systems, has entered into a commercial agreement with Zhejiang Shanshi Medical Device CO., LTD (Shanshi) for distribution of the company's T-Line technology. The agreement will permit Shanshi to market, pending final regulatory approvals, the company's newest TL-300 throughout China, Taiwan, and Hong Kong. Under terms of the 5-year exclusive supply relationship, the parties have agreed on cumulative orders of up to $US 40 million.
Shanshi will initially target the T-line into the Chinese operating room (OR) and intensive care unit (ICU) markets. The T-Line technology platform accurately and continuously captures a patient's beat-to-beat waveform and blood pressure in a completely non-invasive fashion, providing physicians with a stream of real-time hemodynamic data that is not possible using traditional non-invasive blood pressure (cuff) devices. Avoiding the blind-time associated with a deflated or inaccurate cuff can enhance hemodynamic monitoring, which has been definitively linked to improved clinical outcomes.
"The TL-300 represents the future of hemodynamic monitoring in the Chinese market," commented Dr. Xiaodong Du, Shanshi's General Manager. Dr. Du added, "Our pre-marketing efforts have validated our belief that the T-Line can make a dramatic impact in the Asia-Pacific hemodynamic monitoring markets and Shanshi expects to begin full marketing efforts throughout China in 2013."